statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FDA Approves Expanded Use Of Arcutis Biotherapeutics' Eczema Drug For Patients As Young As 6 Years

FDA approved Arcutis Biotherapeutics' sNDA for Zoryve cream 0.15% for mild to moderate atopic dermatitis in patients aged six and older. Zoryve provides a steroid-free treatment option. Significant...

Arcutis Biotherapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Latest Ratings for ARQT
 DateFirmActionFromTo Mar 2022Morgan StanleyMaintainsOverweight Nov 2021Morgan StanleyMaintainsOverweight Jul 2021Morgan StanleyMaintainsOverweight
 View More Analyst...

Arcutis Biotherapeutics (ARQT) Gets a Buy from TD Cowen

In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Arcutis Biotherapeutics (ARQT Research Report), with a price...

Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket

US Futures Coiled Tightly Ahead Of Key CPI Print

US Futures Coiled Tightly Ahead Of Key CPI Print

 Equity futures were set to hold yesterday's gains ahead of today's CPI report, but will move violently either higher or lower after...

Arcutis Biotherapeutics Stock Climbs After Blockbuster Q1 Results

Arcutis Biotherapeutics reports its first-quarter financial results after the bell Tuesday.
read more...

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...

Arcutis Biotherapeutics (NASDAQ:ARQT)  Shares Down 6.2%

Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) dropped 6.2% during mid-day trading on Monday . The stock traded as low as $9.16 and last traded at $9.30. Approximately...

Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve  Cream

Patent challenge initiated by Arcutis BiotherapeuticsNESS ZIONA, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company pioneering treatments...

Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference

WESTLAKE VILLAGE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.

Volume	1.46M
52-Wk High	$13.17
52-Wk Low	$1.76

ARQT Arcutis Biotherapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals